---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-059539"
form_type: "8-K"
ticker: "TNYA"
cik: "0001858848"
company_name: "Tenaya Therapeutics, Inc."
filed_at: "2024-05-14T23:59:59+00:00"
generated_at: "2026-06-02T01:18:28.736386+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Tenaya Q1 net loss $32.2M; cuts 22% workforce; cash runway into H2 2025

## Summary
- Net loss $32.2M ($0.40/share) vs $31.7M ($0.43) in Q1 2023; R&D spend $25.1M.
- Cash $122.2M at Mar 31; Feb follow-on raised $46.8M net; runway into H2 2025.
- Workforce reduced ~22% with $1.3-1.5M severance charges expected in Q2 2024.
- TN-201 initial Phase 1b data expected H2 2024; TN-401 RIDGE-1 sites activated.
- Hired Dr. Whedy Wang as SVP Biometrics.

## SEC filing metadata
- accession: 0000950170-24-059539
- form_type: 8-K
- ticker: TNYA
- cik: 0001858848
- company_name: Tenaya Therapeutics, Inc.
- filed_at: 2024-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01, 2.05
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1858848/000095017024059539/0000950170-24-059539-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1858848/000095017024059539/tnya-20240513.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-059539
- JSON: https://secwatch.observer/filing/0000950170-24-059539.json
- Plain text: https://secwatch.observer/filing/0000950170-24-059539.txt

## Source-grounded claims
- claim_id: bf044cacbbfb859380573874d2438c7f2f08bd58
  claim: Tenaya Therapeutics, Inc. reported financial results for first quarter ended March 31, 2024.
  evidence_excerpt: On May 14, 2024, Tenaya Therapeutics, Inc. (“Tenaya”) issued a press release announcing Tenaya’s financial results for the quarter ended March 31, 2024 (“the Earnings Press Release”). The full text of the Earnings Press Release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1858848/000095017024059539/0000950170-24-059539-index.htm
- claim_id: c3cbce4f0a00810dd7dff2d47fa32e688c5149bc
  claim: Tenaya Therapeutics, Inc. announced a restructuring with charges of $1.3 million to $1.5 million (approximately 22% of the workforce).
  evidence_excerpt: Employees impacted by the Workforce Reduction were notified on May 13, 2024, and represent approximately 22% of the workforce. In connection with the Workforce Reduction, Tenaya estimates that it will incur approximately $1.3 million to $1.5 million, of aggregate charges, primarily related to employee cash severance and continuing health benefits, which costs are expected to be substantially recognized during the second quarter of 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1858848/000095017024059539/0000950170-24-059539-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.